Does continuous-infusion interleukin-2 increase survival in metastatic melanoma?

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 26, Issue 2, 2003, Pages 141-145

  Dillman, Robert O ^a   O'Connor, Audrey A ^b   Simpson, Linda ^b   Barth, Neil M ^b   VanderMolen, Louis A ^b   Vanderplas, Peter ^b  

^a HOAG MEMORIAL HOSPITAL PRESBYTERIAN   (United States)

^b NONE

Author keywords

Contemporary matched controls; IL 2; Metastatic melanoma; Survival

Indexed keywords

INTERLEUKIN 2;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG INFUSION; FEMALE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; IMMUNOTHERAPY; INFUSIONS, INTRAVENOUS; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 0037394641     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200304000-00008     Document Type: Article

References (29)

1. Dillman RO. The clinical experience with interleukin-2 in cancer therapy. Cancer Biother 1994;9:183-209.
2. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985-1993. J Clin Oncol 1999;17:2105-2116.
3. Palmer PA, Vinke J, Evers P, et al. Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinoma. Eur J Cancer 1992;28A:1038-1044.
4. Stoter G, Aamdal S, Rodenhuis S, et al. Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: a multicenter phase II study. J Clin Oncol 1991;9:1687-1691.
5. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987;316:889-897.
6. West WH, Tauer KW, Yannelli JR, et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987;316:898-905.
7. Dillman RO. What to do with IL-2? Cancer Biother Radiopharm 1999;14:423-434.
8. Weiss GR, Margolin KA, Aronson FR, et al. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. J Clin Oncol 1992;10:275-281.
9. Dillman RO, Church C, Barth NM, et al. Long-term survival after continuous infusion interleukin-2. Cancer Biother 1997;12:243-248.
10. Atkins MA, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000;6(suppl 1):S11-14.
11. Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.
12. Johnston SR, Constenia DO, Moore J, et al. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin-2 (IL-2) in patients with metastatic melanoma. Br J Cancer 1998;77:1280-1286.
13. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Prospective randomized trial of the treatment of patients with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 1999;17:968-975.
14. Keilholz U, Eggermont AM. The role of interleukin-2 in the management of stage IV melanoma: the EORTC melanoma cooperative group program. Cancer J Sci Am 2000;6(suppl 1):S99-103.
15. Dillman RO, Oldham RK, Barth NM, et al. Recombinant interleukin-2 and adoptive immunotherapy alternated with dacarbazine therapy in melanoma: a National Biotherapy Study Group trial. J Natl Cancer Inst 1990;82:1345-1349.
16. Dillman RO, Oldham RK, Tauer KW, et al. Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trial. J Clin Oncol 1991;9:1233-1240.
17. Dillman RO, Oldham RK, Barth NM, et al. Continuous interleukin-2 and tumor infiltrating lymphocytes as treatment of advanced melanoma. Cancer 1991;68:1-8.
18. Oldham RK, Stark J, Barth NM, et al. Continuous infusion of interleukin-2 and cyclophosphamide as treatment of advanced cancers: a National Biotherapy Study Group trial. Mol Biother 1991;3:74-78.
19. Oldham RK, Blumenschein G, Schwartzberg L, et al. Combination biotherapy utilizing interleukin-2 and alpha interferon in patients with advanced cancer: a National Biotherapy Study Group trial. Molec Biother 1992;4:4-9.
20. Dillman RO, Church C, Oldham RK, et al. Experience with high-dose continuous infusion interleukin-2 in the treatment of 788 cancer patients. Cancer 1993;71:2358-2370.
21. Dillman RO, Wiemann MC, VanderMolen LA, Bury JM, DePriest C, Church C. Hybrid high-dose bolus/continuous infusion interleukin-2 in patients with metastatic melanoma: a phase II trial of the Cancer Biotherapy Research Group (formerly the National Biotherapy Study Group). Cancer Biother 1997;12:249-255.
22. Dillman RO, Crispin R, Oldham RK. The Cancer Biotherapy Research Group [CBRG], (formerly the National Biotherapy Study Group [NBSG]): a 10-year perspective. Cancer Biother Radiopharm 1997;12:229-242.
23. Dillman RO, Soori G, Wiemann MC, et al. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-α, intravenous combination chemotherapy and oral tamoxifen in the treatment of metastatic melanoma: final results of the Cancer Biotherapy Research Group 94-11. Cancer Biother Radiopharm 2000;15:487-494.
24. Bailar JC III, Mosteller F, eds. Medical uses of statistics. 2nd ed. Boston: NEJM Books, 1992.
25. Fisher LD, van Belle G. Biostatistics: a methodology for the health sciences. New York: John Wiley & Sons, 1993.
26. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000;342:1887-1892.
27. Benson K, Hartz A. A comparison of observational studies and randomized controlled trials. N Engl J Med 2000;342:1878-1886.
28. Meyer T, Merkel S, Goehl J, et al. Surgical therapy for distant metastases of malignant melanoma. Cancer 2000;89:1983-1991.
29. Flaherty LE. Rationale for Intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone inpatients with metastatic melanoma. Cancer J Sci Am 2000;6(suppl 1):S15-20.